A detailed history of Ubs Group Ag transactions in Pro Mis Neurosciences Inc. stock. As of the latest transaction made, Ubs Group Ag holds 250 shares of PMN stock, worth $447. This represents 0.0% of its overall portfolio holdings.

Number of Shares
250
Previous 5,926 95.78%
Holding current value
$447
Previous $6,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$1.28 - $2.81 $7,265 - $15,949
-5,676 Reduced 95.78%
250 $0
Q4 2023

Feb 09, 2024

BUY
$0.97 - $2.0 $5,648 - $11,646
5,823 Added 5653.4%
5,926 $6,000
Q3 2023

Nov 09, 2023

SELL
$1.52 - $6.19 $913 - $3,720
-601 Reduced 85.37%
103 $0
Q2 2023

Aug 11, 2023

BUY
$3.7 - $8.14 $2,604 - $5,730
704 New
704 $2,000
Q4 2022

Feb 08, 2023

SELL
$4.33 - $6.08 $2,459 - $3,453
-568 Reduced 19.51%
2,344 $10,000
Q3 2022

Nov 10, 2022

BUY
$5.08 - $9.25 $14,792 - $26,936
2,912 New
2,912 $18,000

Others Institutions Holding PMN

About ProMIS Neurosciences Inc.


  • Ticker PMN
  • Exchange OTC
  • Description
  • ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms t...
More about PMN
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.